The NTIS website and supporting ordering systems are undergoing a major upgrade from 8PM on September 25th through approximately October 6. During that time, much of the functionality, including subscription and product ordering, shipping, etc., will not be available. You may call NTIS at 1-800-553-6847 or (703) 605-6000 to place an order but you should expect delayed shipment. Please do NOT include credit card numbers in any email you might send NTIS.
Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website; (3) the federal government Internet portal; or (4) a web search conducted using a commercial search engine such as
Accession Number PB2014-100139
Title Chronic Fatigue Syndrome and Myalgic Encephalomyelitis. Public Meeting: April 24, 2013.
Publication Date Sep 2013
Media Count 23p
Personal Author N/A
Abstract On April 25, 2013, FDA held a public meeting to hear perspectives from patients with chronic fatigue syndrome (CFS) and myalgic encephalomyelitis (ME) about their disease, its impact on their daily life, and currently available therapies. For this meeting and summary report, the terms CFS, ME, and CFS and ME are used interchangeably in describing the conditions. CFS and ME is a serious disease or set of diseases for which there are currently no FDA-approved therapies.
Keywords Chronic Fatigue Syndrome(CTS)
Food and Drug Administration(FDA)
Health care
Health conditions
Myalgic Encephalomyelitis(ME)
Patient-Focused Drug Development Initiative
Prescription drugs
Public health

Source Agency Food and Drug Administration
NTIS Subject Category 57Q - Pharmacology & Pharmacological Chemistry
57U - Public Health & Industrial Medicine
44 - Health Care
92C - Social Concerns
Corporate Author Food and Drug Administration, Rockville, MD. Center for Drug Evaluation and Research.
Document Type Technical report
Title Note N/A
NTIS Issue Number 1401
Contract Number N/A

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader